Over the past 12 months, 5 insiders at Royalty Pharma plc filed 60 open-market SEC Form 4 transactions on RPRX: 0 purchases worth $0 and 60 sales worth $69.1M. Insiders have been net sellers over this period. The most recent filing was on Jul 1, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 26 | Marshall UristEVP, Research & Investments | SELL | 9.1K | $55.88 | $508K |
| Jun 30, 26 | Christopher HiteEVP & Chairman, Partnering | SELL | 97.4K | $57.10 | $5.5M |
| May 26, 26 | Terrance P. CoyneEVP & CFO | SELL | 64.4K | $53.98 | $3.5M |
| Apr 28, 26 | Terrance P. CoyneEVP & CFO | SELL | 32.9K | $49.78 | $1.6M |
| Mar 23, 26 | Terrance P. CoyneEVP & CFO | SELL | 32.9K | $45.53 | $1.5M |
| Mar 2, 26 | Terrance P. CoyneEVP & CFO | SELL | 22.5K | $47.01 | $1.0M |
| Feb 23, 26 | Terrance P. CoyneEVP & CFO | SELL | 32.9K | $45.32 | $1.5M |
| Feb 4, 26 | Terrance P. CoyneEVP & CFO | SELL | 19.1K | $43.29 | $826K |
| Feb 3, 26 | Terrance P. CoyneEVP & CFO | SELL | 108.8K | $42.84 | $4.7M |
| Feb 2, 26 | Terrance P. CoyneEVP & CFO | SELL | 102.6K | $42.08 | $4.3M |
| Jan 30, 26 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $41.09 | $822K |
| Jan 23, 26 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $40.26 | $805K |
| Jan 20, 26 | Terrance P. CoyneEVP & CFO | SELL | 65.8K | $39.35 | $2.6M |
| Jan 16, 26 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $39.52 | $790K |
| Jan 9, 26 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $40.78 | $816K |
| Jan 2, 26 | Terrance P. CoyneEVP & CFO | SELL | 65.8K | $38.42 | $2.5M |
| Jan 2, 26 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $38.48 | $770K |
| Dec 26, 25 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $39.32 | $786K |
| Dec 19, 25 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $38.38 | $768K |
| Dec 18, 25 | George W. LloydEVP, Investments & CLO | SELL | 30.7K | $38.50 | $1.2M |
| Dec 17, 25 | George W. LloydEVP, Investments & CLO | SELL | 79.3K | $38.57 | $3.1M |
| Dec 16, 25 | Marshall UristEVP, Research & Investments | SELL | 20.0K | $38.32 | $766K |
| Dec 15, 25 | Terrance P. CoyneEVP & CFO | SELL | 65.8K | $38.36 | $2.5M |
| Dec 5, 25 | Marshall UristEVP, Research & Investments | SELL | 23.3K | $39.15 | $914K |
| Dec 3, 25 | George W. LloydEVP, Investments & CLO | SELL | 110.0K | $39.77 | $4.4M |
| Dec 1, 25 | Terrance P. CoyneEVP & CFO | SELL | 65.8K | $39.87 | $2.6M |
| Dec 1, 25 | Marshall UristEVP, Research & Investments | SELL | 23.3K | $39.93 | $932K |
| Nov 24, 25 | Terrance P. CoyneEVP & CFO | SELL | 55.1K | $38.67 | $2.1M |
| Nov 19, 25 | George W. LloydEVP, Investments & CLO | SELL | 47.8K | $39.03 | $1.8M |
| Nov 17, 25 | Terrance P. CoyneEVP & CFO | SELL | 65.8K | $39.30 | $2.6M |
| Aug 11, 25 | Gregory NordenDirector | SELL | 33.5K | $36.23 | $1.2M |
| Jan 4, 24 | Rory B RiggsDirector | SELL | 35.7K | $27.55 | $984K |
| Jan 3, 24 | Rory B RiggsDirector | SELL | 199.1K | $27.79 | $5.5M |
| Jan 2, 24 | Rory B RiggsDirector | SELL | 235.2K | $28.52 | $6.7M |
| Dec 29, 23 | Avara Management LtdDirector,TenPercentOwner | SELL | 65.8K | $28.04 | $1.8M |
| Dec 28, 23 | Mario Germano GiulianiTenPercentOwner | SELL | 209.9K | $28.20 | $5.9M |
| Dec 27, 23 | Mario Germano GiulianiTenPercentOwner | SELL | 41.7K | $28.01 | $1.2M |
| Dec 15, 23 | Mario Germano GiulianiTenPercentOwner | SELL | 10.2K | $28.01 | $287K |
| Dec 14, 23 | Avara Management LtdDirector,TenPercentOwner | SELL | 364.4K | $28.91 | $10.5M |
| Dec 13, 23 | Avara Management LtdDirector,TenPercentOwner | SELL | 307.9K | $28.95 | $8.9M |
| Aug 10, 23 | Terrance P. CoyneEVP & CFO | SELL | 37.5K | $30.75 | $1.2M |
| Aug 9, 23 | Terrance P. CoyneEVP & CFO | SELL | 37.5K | $30.72 | $1.2M |
| Jul 13, 23 | Terrance P. CoyneEVP & CFO | SELL | 37.5K | $30.93 | $1.2M |
| Jul 12, 23 | Terrance P. CoyneEVP & CFO | SELL | 37.5K | $31.07 | $1.2M |
| Jun 28, 23 | Pablo G. LegorretaCEO, Chairman of the Board | BUY | 130.0K | $29.51 | $3.8M |
| Jun 13, 23 | Pablo G. LegorretaCEO, Chairman of the Board | BUY | 45.0K | $32.78 | $1.5M |
| Jun 12, 23 | Pablo G. LegorretaCEO, Chairman of the Board | BUY | 45.0K | $33.00 | $1.5M |
| Jun 6, 23 | George W. LloydEVP, Investments & CLO | SELL | 79.1K | $33.82 | $2.7M |
| Jun 5, 23 | George W. LloydEVP, Investments & CLO | SELL | 19.2K | $33.54 | $644K |
| Jun 2, 23 | George W. LloydEVP, Investments & CLO | SELL | 92.2K | $33.65 | $3.1M |
Over the past 12 months, insiders at Royalty Pharma plc filed 0 open-market purchases worth $0 and 60 sales worth $69.1M on RPRX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 1, 26.
The largest recent open-market RPRX insider purchase in our data was $3.8M by Pablo G. Legorreta, CEO, Chairman of the Board, filed on Jun 28, 23.
5 different insiders at Royalty Pharma plc filed open-market SEC Form 4 transactions on RPRX over the last 12 months.
InsiderTape plots every RPRX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Royalty Pharma plc insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →